
The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index, which measures the performance of the medical equipment sector of the U.S. equity market, as defined by S&P Dow Jones Indices LLC. The index includes medical equipment companies, including manufacturers and distributors of medical devices such as magnetic resonance imaging scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.
Is IHI's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

Looking for broad exposure to the Healthcare - Medical Devices segment of the equity market? You should consider the iShares U.S. Medical Devices ETF (IHI), a passively managed exchange traded fund launched on May 1, 2006.

iShares U.S. Medical Devices ETF is rated a sell due to historical underperformance, high concentration risk, and elevated valuation. IHI's top three holdings—ABT, ISRG, SYK—comprise nearly 43% of the portfolio, amplifying downside risk if growth falters or valuations compress. The ETF's 34x PE and sub-0.5% yield create an unattractive risk-reward profile, especially given its 18–20% volatility and minimal income.

iShares U.S. Medical Devices ETF (NYSEARCA:IHI - Get Free Report) was the target of some unusual options trading on Monday. Stock investors bought 20,198 put options on the company. This is an increase of 524% compared to the typical volume of 3,237 put options. Institutional Trading of iShares U.S. Medical Devices ETF Hedge funds have

Launched on May 1, 2006, the iShares U.S. Medical Devices ETF (IHI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Medical Devices segment of the equity market.

I reiterate a Hold rating on the iShares US Medical Devices ETF despite its 20% YTD decline and ongoing technical weakness. IHI's valuation is reasonable but not compelling, with a P/E of 18.8x and a 10.3% long-term EPS growth rate. The ETF is highly concentrated, with its top 10 holdings accounting for 75% of the portfolio and a low dividend yield at 0.45%.